Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Gains from Investment Securities: 2013-2025

Historic Gains from Investment Securities for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $6.9 million.

  • Amphastar Pharmaceuticals' Gains from Investment Securities rose 11.46% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 86.07%. This contributed to the annual value of $6.7 million for FY2024, which is 14.26% down from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Gains from Investment Securities is $6.9 million, which was up 137.18% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Gains from Investment Securities registered a high of $35.8 million during Q1 2024, and its lowest value of $1.0 million during Q1 2021.
  • Its 3-year average for Gains from Investment Securities is $8.6 million, with a median of $6.9 million in 2025.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Gains from Investment Securities soared by 1,430.24% in 2024, and later slumped by 78.13% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $2.6 million in 2021, then slumped by 56.08% to $1.1 million in 2022, then soared by 368.12% to $5.4 million in 2023, then tumbled by 31.39% to $3.7 million in 2024, then grew by 11.46% to $6.9 million in 2025.
  • Its last three reported values are $6.9 million in Q3 2025, $2.9 million for Q2 2025, and $7.8 million during Q1 2025.